Behold.ai vs Gleamer (2026)
Two European radiograph companies separated by the most consequential decision in imaging AI, whether a human still looks. Behold auto reports chest films it classifies as high confidence normal, removing them from the worklist entirely, and it publishes the performance numbers that autonomy requires in peer reviewed venues. Gleamer detects fractures, effusions and dislocations on trauma radiographs with the reader deciding every case, and holds a clearance covering adult and pediatric use reported to be unique in that segment. They read different films, so a department would rarely choose between them. What the pair shows is the evidence gradient: the moment a product stops handing a study to a radiologist, the false negative rate at its operating threshold stops being interesting and becomes the only thing that matters.
- It removes studies from the worklist entirely by auto reporting chest radiographs classified as high confidence normal, which is genuine autonomy inside a bounded task.
- The numbers that matter for that autonomy are published in peer reviewed venues, and the confidence threshold is itself the governance mechanism.
- For a service drowning in normal chest films, removing them from the queue is a different economic proposition from reading them faster.
- Its trauma radiography clearance covers adult and pediatric use, reported to be unique in that segment, with a strong clearance study design behind it.
- The reader retains the decision on every study, which is the conventional and lower risk configuration.
- Distribution through several imaging platforms means adoption does not depend on a single integration path.
This comparison is published by AI Health Index, an independent research platform that compares healthcare AI vendors objectively. Behold.ai and Gleamer are each graded against the same capability taxonomy, from each vendor's own public materials and the regulatory record, under the AI Health Index verification standard. No vendor pays for placement, and no vendor has reviewed this page. How this evidence is graded
Plain facts
| Fact | Behold.ai | Gleamer |
|---|---|---|
| Primary category | Radiology & Imaging AI | Radiology & Imaging AI |
| Founded | 2015 | 2017 |
| Headquarters | London, United Kingdom | Saint-Mandé, France |
| Website | behold.ai | gleamer.ai |
Side by Side
Select any grade to read the note behind it.
Each vendor in one paragraph
Written to be quoted whole. Each paragraph opens the AI Health Index profile of the vendor: what the product is, who buys it and what it does.
UK company whose red dot platform sits at the autonomous end of imaging AI: it reports chest X-rays it classifies as High Confidence Normal autonomously, removing them from the radiologist worklist (about 15 percent of studies, according to the company), triages suspected lung cancer for urgent reporting, and has a companion CT head product. Work published in Clinical Radiology reported a 0.33 percent error rate on the auto reported studies and a 60 percent reduction in missed lung cancers when triage ran alongside consultant radiologists.
Source: AI Health Index, August 2026
Gleamer SAS is a radiology AI company based in Saint-Mandé, on the edge of Paris, and since 2 March 2026 part of DeepHealth, the digital health subsidiary of the US imaging services operator RadNet, Inc. RadNet announced the all cash acquisition at up to 230 million euros, about 215 million at closing plus a 15 million contingent milestone. Gleamer's site and products keep the Gleamer name.
Source: AI Health Index, August 2026
Questions buyers ask
How do Behold.ai and Gleamer work with the EHR?
For Behold.ai, the how it works page states that after analysis it sends an electronic notification back to the trust RIS, or to PACS where reporting is PACS driven, marking each examination as normal or abnormal and prioritizing it in the existing worklist; for auto reported studies that notification is the report.
Gleamer has been part of DeepHealth, the digital health subsidiary of RadNet, since March 2026, and nothing published says whether the products now run inside DeepHealth's platform or remain available on other vendors' archives. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How are Behold.ai and Gleamer priced and sold?
In Behold.ai's case, the original company entered administration in January 2025 after failing to win NHS AI Diagnostic Fund contracts, NICE withdrew the product from its recommendations the following month, and a successor acquired the assets and relaunched it.
For Gleamer, the packaging and the owner are public. The products are sold as modules of the Gleamer Copilot suite, and since March 2026 Gleamer has been part of DeepHealth, the digital health subsidiary of RadNet, so contracting may run through DeepHealth. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
How do Behold.ai and Gleamer handle patient data?
With Behold.ai, the how it works page states that images reach the platform over an encrypted VPN and that all patient examination data resides in fully NHS accredited data centers.
When Gleamer receives patient data from a customer, including imaging examinations and reports, it acts as the customer's processor and works on pseudonymized data, and where the customer authorizes it, Gleamer may anonymize pseudonymized patient data and use the anonymized result for its own purposes, including training and developing its products. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Which settings and specialties do Behold.ai and Gleamer cover?
For Behold.ai, the settings on record are NHS trust radiology departments.
With Gleamer, the suite now claims far wider coverage, described by the company as covering all imaging modalities, with products for chest X-ray, chest CT, bone CT, breast imaging, brain MRI and lumbar spine MRI. Validation for those is not summarized on the home page, and ChestView and BoneMetrics have their own FDA summaries. From the AI Health Index, drawn from each vendor's own published materials and the regulatory record, verified August 4, 2026. No vendor pays for placement.
Related comparisons
Other published head to head assessments involving these vendors or their closest peers. The full set for this category is on the Clinical Decision Support page.
The autonomy difference sets the evidence bar: an auto reporting classifier needs its false negative rate at the operating threshold published and locally revalidated, because a missed finding on an auto reported film is never seen by anyone, while a detection aid leaves the radiologist reading every study.
Behold's regulatory standing is multi jurisdictional and unsettled and its corporate history complicates the identity of the contracting entity, both of which should be established before deployment. Neither publishes a security attestation or pricing.